Rome, October 1 — The mechanics here are straightforward: immunotherapy, a breakthrough in cancer treatment, has generated significant revenue for biotechnology companies, with the global cancer immunotherapy market valued at approximately $100 billion in 2022 and projected to exceed $200 billion by 2030. The story of former President Jimmy Carter’s treatment for melanoma is a case in point. His treatment involved a class of drugs known as immune checkpoint inhibitors, which enable the body’s immune system to recognize and attack cancer cells.
This treatment was not the result of chance but the product of decades of scientific research into immune system mechanisms, much of it funded by the U.S. federal government through agencies such as the National Institutes of Health.
Follow the Money
Private investors provided critical early-stage funding for experimental approaches that many in the scientific community initially doubted would succeed. The commercial success of these therapies has since generated significant revenue for biotechnology companies; for example, Merck & Co. reported over $17 billion in global sales of Keytruda in 2023, reflecting the drug’s widespread adoption in oncology.
The catch is that the development and distribution of immunotherapies have created a growing market sector, driven by investment in biotech firms, influencing stock valuations in the healthcare sector, and prompting strategic partnerships between pharmaceutical companies and research institutions. On closer reading, the growth of this market sector has been fueled by the success of immune checkpoint inhibitors, such as pembrolizumab, which was reportedly part of Carter’s treatment regimen.
The Role of Government Funding
The U.S. federal government has played a crucial role in funding the research that led to the development of immunotherapies. Agencies such as the National Institutes of Health have provided decades of funding for scientific research into immune system mechanisms. This funding has been instrumental in advancing the field and bringing new treatments to market.
But the sustainability of such progress depends on continued funding, supportive regulatory frameworks, and patient participation in research—elements described as weakening in the current ecosystem despite the strength of the underlying science. As the global cancer immunotherapy market continues to grow, it will be important to watch how the US administration responds to the need for continued funding and support for immunotherapy research.
Looking Ahead
As the market for immunotherapies continues to expand, investors and patients alike will be watching to see how the major players in the field navigate the challenges and opportunities ahead. With the global cancer immunotherapy market projected to exceed $200 billion by 2030, the stakes are high, and the potential rewards are significant. The key will be to balance the need for continued innovation and investment with the need for sustainable and equitable access to these life-changing treatments.
